FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W80186827> ?p ?o ?g. }

• W80186827 endingPage "6" @default.
• W80186827 startingPage "233" @default.
• W80186827 abstract "Some studies have demonstrated the efficacy and safety of intraperitoneal (i.p.) urokinase in the resolution of recurrent or relapsing peritonitis, while others have not. Most studies were small, and they varied in methodology. Furthermore, the role of i.p. urokinase in shortening the duration of peritonitis or in preventing recurrence after initial peritonitis has not been examined. In addition, no previous studies have examined the role of i.p. urokinase in preventing, after first infection, catheter loss due to unresolving (resistant) peritonitis. Over a period of 3 years, we prospectively randomized into two groups all peritoneal dialysis (PD) patients who developed a first episode of peritonitis. Group I (n = 40) received i.p. urokinase on the first day of diagnosis (5000 IU intraluminally in the peritoneal catheter and left for 4 hours before next exchange). Group II (n = 40) received no urokinase. The duration of peritonitis was assessed by daily PD fluid white blood cell (WBC) count. Indications for catheter removal were: persistent peritonitis after four days from initiation of antibiotic therapy, or peritonitis with multiple organisms, suggesting bowel perforation. No statistically significant difference was seen between the two groups in regard to primary cause of end-stage renal disease (ESRD), age, sex, race, weight, type of dialysis [continuous ambulatory peritoneal dialysis (CAPD), automated peritoneal dialysis (APD), continuous cycling peritoneal dialysis (CCPD)], or duration of dialysis prior to first peritonitis. No statistically significant difference was seen between the two groups in the duration of peritonitis or in the severity of symptoms and signs of peritonitis. Neither was any difference seen in the peritonitis recurrence or relapse rate (10% in the urokinase group vs 7.5% in the control group). Nine patients lost their catheters (3 in the urokinase group: 1 Pseudomonas aeruginosa and 2 Candida tropicalis; 6 in the control group: 1 Klebsiella pneumonia, 1 enterococcus, 2 Pseudomonas aeruginosa, and 2 Candida tropicalis). The difference in the rate of catheter loss between the two groups was not statistically significant; it appeared to relate to the type of organism rather than to the response to urokinase. In conclusion, i.p. urokinase plays no significant role in shortening the course of peritonitis or in preventing recurrence or loss of the PD catheter. Loss of PD catheters in patients having their first peritonitis appears to be related primarily to the type of organism causing the infection." @default.
• W80186827 created "2016-06-24" @default.
• W80186827 creator A5010690783 @default.
• W80186827 creator A5014104597 @default.
• W80186827 creator A5066917583 @default.
• W80186827 creator A5086339240 @default.
• W80186827 creator A5088149219 @default.
• W80186827 date "2000-01-01" @default.
• W80186827 modified "2023-09-23" @default.
• W80186827 title "Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients." @default.
• W80186827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11045301" @default.
• W80186827 hasPublicationYear "2000" @default.
• W80186827 type Work @default.
• W80186827 sameAs 80186827 @default.
• W80186827 citedByCount "11" @default.
• W80186827 countsByYear W801868272012 @default.
• W80186827 countsByYear W801868272014 @default.
• W80186827 countsByYear W801868272015 @default.
• W80186827 countsByYear W801868272016 @default.
• W80186827 countsByYear W801868272017 @default.
• W80186827 countsByYear W801868272020 @default.
• W80186827 crossrefType "journal-article" @default.
• W80186827 hasAuthorship W80186827A5010690783 @default.
• W80186827 hasAuthorship W80186827A5014104597 @default.
• W80186827 hasAuthorship W80186827A5066917583 @default.
• W80186827 hasAuthorship W80186827A5086339240 @default.
• W80186827 hasAuthorship W80186827A5088149219 @default.
• W80186827 hasConcept C126322002 @default.
• W80186827 hasConcept C141071460 @default.
• W80186827 hasConcept C2776892390 @default.
• W80186827 hasConcept C2778063415 @default.
• W80186827 hasConcept C2779056158 @default.
• W80186827 hasConcept C2779978075 @default.
• W80186827 hasConcept C2780199535 @default.
• W80186827 hasConcept C2781267111 @default.
• W80186827 hasConcept C2909406889 @default.
• W80186827 hasConcept C71924100 @default.
• W80186827 hasConcept C90924648 @default.
• W80186827 hasConceptScore W80186827C126322002 @default.
• W80186827 hasConceptScore W80186827C141071460 @default.
• W80186827 hasConceptScore W80186827C2776892390 @default.
• W80186827 hasConceptScore W80186827C2778063415 @default.
• W80186827 hasConceptScore W80186827C2779056158 @default.
• W80186827 hasConceptScore W80186827C2779978075 @default.
• W80186827 hasConceptScore W80186827C2780199535 @default.
• W80186827 hasConceptScore W80186827C2781267111 @default.
• W80186827 hasConceptScore W80186827C2909406889 @default.
• W80186827 hasConceptScore W80186827C71924100 @default.
• W80186827 hasConceptScore W80186827C90924648 @default.
• W80186827 hasLocation W801868271 @default.
• W80186827 hasOpenAccess W80186827 @default.
• W80186827 hasPrimaryLocation W801868271 @default.
• W80186827 hasRelatedWork W1971805669 @default.
• W80186827 hasRelatedWork W1972223454 @default.
• W80186827 hasRelatedWork W2012081919 @default.
• W80186827 hasRelatedWork W2032863549 @default.
• W80186827 hasRelatedWork W2032950402 @default.
• W80186827 hasRelatedWork W2188749248 @default.
• W80186827 hasRelatedWork W2296078103 @default.
• W80186827 hasRelatedWork W2405060036 @default.
• W80186827 hasRelatedWork W2432782501 @default.
• W80186827 hasRelatedWork W56987915 @default.
• W80186827 hasVolume "16" @default.
• W80186827 isParatext "false" @default.
• W80186827 isRetracted "false" @default.
• W80186827 magId "80186827" @default.
• W80186827 workType "article" @default.